Filtrer par genre

Dr. John Campbell

Dr. John Campbell

Campbellteaching

Hello Everyone, My name is John Campbell and I am a retired Nurse Teacher and former clinical nurse based in England. I also do some teaching in Asia and Africa when time permits. These videos are to help students to learn the background to all forms of health care. My PhD focused on the development of open learning resources for nurses nationally and internationally. LinkedIn profile, https://www.linkedin.com/in/dr-john-campbell-5256223b/ Twitter, https://twitter.com/Johnincarlisle Disclaimer; These media including videos, book, e book, articles, podcasts are not peer-reviewed. They should never replace individual clinical judgement from your own health care provider. No media-based material on this channel is suitable for using as professional medical advice. All comments are also for educational purposed only and must never replace advice from your own health care provider

1159 - Joe Rogan medicines clip
0:00 / 0:00
1x
  • 1159 - Joe Rogan medicines clip

    Exploring the Anticancer Potential of Fenbendazole: A Review of Anecdotal Case Reports and Emerging Evidence (2025)Uploaded 10-02-25https://www.onedaymd.com/2025/01/anticancer-potential-fenbendazole.htmlA compilation of 80 case reports across various cancer types, including breast, lung, colorectal, and pancreatic cancersWhile these anecdotal accounts suggest potential anticancer effects of fenbendazole, the lack of controlled clinical trials necessitates caution. Healthcare professionals should be consulted before considering fenbendazole as a treatment option.There has been growing popularity in recent years for the use of Fenbendazole (FBZ) as a single agent or supplementary therapeuticMethodsReports were categorized by cancer type, and outcomes were assessed based on self-reported measures such as tumor regression, remission status, and overall survival. ResultsThese findings, while compelling, must be interpreted cautiously due to the inherent limitations of the data sources. Breast CancerEight cases of breast cancer reported outcomes such as tumor shrinkage or remission.A majority of these cases involved early to moderate-stage disease, with some patients combining fenbendazole with standard treatments like chemotherapy and hormonal therapy.One notable case involved a patient with metastatic triple-negative breast cancer achieving remission after six months of fenbendazole use,alongside a ketogenic diet and immune-supportive supplements.Lung CancerNine cases, highlighted improved survival rates and tumor regression.One patient with advanced NSCLC demonstrated significant tumor shrinkage within three months of incorporating fenbendazole alongside checkpoint inhibitors.Colorectal CancerIn nine cases, patients reported tumor reduction, remission, or disease stabilization.The most striking outcome was from a patient with stage IV colorectal cancer achieving no evidence of disease (NED) status after integrating fenbendazole with conventional therapies and dietary modifications.Pancreatic CancerEight cases involved pancreatic cancer, an aggressive malignancy with limited treatment options.Outcomes were generally less pronounced than in other cancersOther Cancer TypesReports included melanoma, prostate cancer, glioblastoma, and ovarian cancer, with mixed outcomes. Some patients indicated significant clinical improvement, including reduced tumor markers and alleviated symptoms.Combination Therapies, with conventional cancer treatments (e.g., chemotherapy, radiotherapy, immunotherapy), ? making fenbendazole’s specific effects. Supplement Use: Many used supportive supplements, (e.g., D3, C), zinc, curcumin, ? synergistic effectsConsistency and Dosage: Regular and sustained use of fenbendazole appeared to correlate with better-reported outcomes. Dosages ranged from 222 mg (a standard veterinary dose) to 1 gram per day, depending on individual protocols.LimitationsSample size, (N=80)Self-Reported DataConcurrent TherapiesPotential Mechanisms of ActionMicrotubule DisruptionMetabolic Effects, (inhibits glucose uptake in cancer cells)Immune Modulation, (may enhance immune responses)DiscussionConsistency of positive outcomes across diverse cancer types suggests a potential biological effect that merits further investigation. The pattern of case reports also suggests that fenbendazole may exhibit broad-spectrum anticancer properties.It is imperative that patients consult healthcare professionals before considering fenbendazole as a treatment option. Future DirectionsControlled Clinical TrialsMechanistic StudiesCombination Therapy ResearchConclusionThe consistency of anecdotal outcomes, supported by plausible preclinical mechanisms, positions fenbendazole as a promising candidate for further investigation in oncology. I@JayMitchell-c7i I am Learn more about your ad choices. Visit megaphone.fm/adchoices

    Fri, 06 Nov 2026
  • 1158 - Review, infections and complications

    If you would like John’s text books, (it is free to download the PDFs)Uploaded 07-03-22Link to free download of my 2 textbookshttp://159.69.48.3/Physiology book in hard copyhttps://www.ebay.co.uk/itm/154770452796?mkevt=1&mkcid=16&mkrid=710-127635-2958-0Avoidable mortality rates at highest level since 2010In 2020, 22.8% of all deaths in Great Britain (GB) were considered avoidable. This figure represents about 153,000 of the total 672,000 deaths.Long COVID and mental disorders in school agePrimary age with long covid30.0% had a probable mental disorderPrimary age without long covid7.7.0% had a probable mental disorderPrimary aged1% have experienced long covidSecondary school age with long covid22.6% had a probable mental disorderSecondary school age without long covid13.6% had a probable mental disorderSecondary aged2.7% have experienced long covidUK prevalence, week to end of February1,933,500 people (1 in 30) in England94,200 people (1 in 30) in Wales106,300 people (1 in 17) in Northern Ireland280,500 people (1 in 19) in ScotlandDeaths involving COVID-19 continue to fallWeek ending 18 February 2022969 deaths in the week217 fewer than the previous weekTotal deaths in the week, 12,742,6.4% below the five-year averageOf the 863 deaths registered (where covid was mentioned),64.8% (559 deaths) recorded as the underlying cause of deathPresence of antibodiespreviously had COVID-19 infection or been vaccinatedWeek beginning 31 January 202298.2% in England 97.9% in Wales 98.2% in Northern Ireland 98.2% in ScotlandLong COVID have had it for at least a yearAs of the end of January 20221.5 million people (2.4%) living with long COVID(over 4 weeks)685,000 (45%) symptoms at least a year65% (989,000) of those with self-reported long COVID,it affected their day-to-day activitiesFatigue, 51%Prevalenceaged 35 to 49 years, females, people living in more deprived areas, working in teaching and education, social care or healthcare, those with another activity-limiting health condition or disability Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

    Fri, 06 Nov 2026
  • 1157 - CDC, increased infection risk in vaccinated

    BA.2.86 may be more capable of causing infection in people who have previously had COVID-19 or who have received COVID-19 vaccines. Uploaded 29-08-23New variant and vaccine escapeRisk Assessment Summary for SARS CoV-2 Sublineage BA.2.86https://www.cdc.gov/respiratory-viruses/whats-new/covid-19-variant.htmlhttps://www.medscape.com/s/viewarticle/995810?ecd=wnl_recnlnew1_ous_230828_MSCPEDIT_etid5795536&uac=127834AR&impID=5795536BA.2.86, detected in Denmark and IsraelAt least two cases in the United States. UK Health Security Agency, UK case, no recent travel historyCases not epidemiologically linked(therefore already widespread)Multiple genetic differences from previous SARS-CoV-2Existing tests appear to be effectiveBA.2.86 may be more capable of causing infection in people who have previously had COVID-19 or who have received COVID-19 vaccines. ? stimulation of T suppressor (regulatory) cells? stimulation of IgG4https://www.science.org/doi/10.1126/sciimmunol.adg7327No evidence BA.2.86 causing more severe illness. Updated vaccines will be available as early as mid-SeptemberWhat can you do to protect yourself and others as we learn more?Get your COVID-19 vaccines, as recommendedhttps://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.htmlCOVID-19 Vaccines Are Safe, Effective, and FreeEveryone 6 months and older should get an updated COVID-19 vaccine.BA.2.86https://www.nature.com/articles/d41586-023-02656-9Many spike protein changes(explain vaccine immune escape)Could out compete common EG.5(Latest COVID-19 booster vaccines are based on XBB.1.5)Jesse Bloom, viral evolutionary biologist, Fred Hutchinson Cancer Center Seattle, Washington“I don’t think anybody needs to be alarmed by this,” “The most likely scenario is that this variant fizzles out, and in a month nobody other than people like me even remember that it existed.”Even if BA.2.86 does becomes widespread, and proves adept at dodging neutralizing antibodies, which seems likely, on the basis of its set of spike mutations, other forms of immunity will probably stop most people from getting seriously ill if they are infected Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

    Thu, 05 Nov 2026
  • 1156 - Excess deaths in young adults

    Mortality Trends Among Early Adults in the United States, 1999-2023Uploaded 10-02-25https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829783US population groups, ages 25-44 years, 1999 – 2023All cause mortalityOther natural causes of deathTransportAlcohol relatedHomicideEndocrine, nutrition, metabolicDigestiveCirculatoryCancersMutually exclusive underlying cause-of-death categories were adapted from prior workUsed baseline of 1999 to 2010, to project expected mortality trends for 2011 to 2023.We analyzed 3, 392, 364 deaths among the full US population aged 25-44 years from 1999 to 2023. In 2021, all-cause excess mortality was nearly 3 times what it had been in 2019(116.2 vs 41.7 deaths per 100 000 population). In 2023, excess mortality decreased to79.1 deaths per 100 000 population.Early adult mortality was 70.0% higher in 2023 than it would have been had pre-2011 trends continued, reflecting 71, 124 excess deaths.Although mortality rates decreased after the core pandemic years, excess mortality remained higher than expected based on prepandemic levels. Increases in early adult mortality can signal population risks that may become more pronounced as these cohorts age. These results suggest the possibility of a worsening mortality crisis unless these trends are reversed. The 2 distinct phases of increasing mortality (before and after 2020) may also suggest the need to attend to ongoing consequences of the COVID-19 pandemic,causes of death related to long-term consequences of infection, medical disruption, and social dislocation—and to deleterious health trends that predated it. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

    Thu, 05 Nov 2026
  • 1155 - The Pfizer documents

    Public Health and Medical Professionals for Transparency, Pfizer / FDA FOIUploaded 09-03-22https://phmpt.orgRequest, Freedom of Information Act (FOIA) https://phmpt.org/wp-content/uploads/2021/10/IR0546-FDA-Pfizer-Approval-FINAL.pdfAgainst FDAhttps://phmpt.org/wp-content/uploads/2021/10/001-Complaint-101021.pdfThe court orderhttps://phmpt.org/wp-content/uploads/2022/02/056-ORDER-GRANTING-IN-PART-THE-MOTION-TO-MODIFY-THE-PRODUCTION-SCHEDULE-AND-ADDOPTS-THE-JOINT-STATUS-REPORT-MODIFIED-AGREED-PRODUCTION-SCHEDULE.pdfList of downloadable documentshttps://phmpt.org/pfizers-documents/5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021 https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdfAdverse event reports 01 December 2020 through 28 February 2021 Cumulatively, through 28 February 2021, a total of 42,086 case reports (25,379 medically confirmed and 16,707 non-medically confirmed) containing 158,893 events. Most cases (34,762) were received from United States (13,739), United Kingdom (13,404) Italy (2,578), Germany (1,913), France (1,506), Portugal (866) and Spain (756)the remaining 7,324 were distributed among 56 other countries. Fatal, 1,223Since Dec. 11, 2020, the Pfizer-BioNTech COVID-19 Vaccine has been available under EUA https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine(Approval, 21st August 2021)Acting FDA Commissioner Janet Woodcock, M.D.While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. Today’s milestone puts us one step closer to altering the course of this pandemic in the U.S.System Organ Classes (SOCs)that contained the greatest number (≥2%) of events, in the overall dataset, were General disorders and administration site conditions (51,335 AEs), Nervous system disorders (25,957), Musculoskeletal and connective tissue disorders (17,283), Gastrointestinal disorders (14,096), Skin and subcutaneous tissue disorders (8,476), Respiratory, thoracic and mediastinal disorders (8,848), Infections and infestations (4,610), Injury, poisoning and procedural complications (5,590), and Investigations (3,693). Cardiovascular AESIs Number of cases: 1403 (3.3% of the total PM dataset), of which 241 are medically confirmed and 1162 are non-medically confirmed; 5. SUMMARY AND CONCLUSION Review of the available data for this cumulative PM experience, confirms a favorable benefit: risk balance for BNT162b2. Peter Marks, M.D., Ph.D., director of FDA’s Center for Biologics Evaluation and Research“Our scientific and medical experts conducted an incredibly thorough and thoughtful evaluation of this vaccine. We evaluated scientific data and information included in hundreds of thousands of pages, conducted our own analyses of Comirnaty’s safety and effectiveness, and performed a detailed assessment of the manufacturing processes, including inspections of the manufacturing facilities,”“….. the public is counting on safe and effective vaccines. The public and medical community can be confident that although we approved this vaccine expeditiously, it was fully in keeping with our existing high standards for vaccines in the U.S."https://childrenshealthdefense.org/defender/fda-releases-pfizer-vaccine-documents/?itm_term=homeAustriahttps://www.nytimes.com/live/2022/03/09/world/covid-19-mandates-cases-vaccineKaroline Edtstadlerthe law, passed in January, in force since early February, not proportionate, relatively mild symptoms experienced by most people who contract Omicron Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

    Wed, 04 Nov 2026
Afficher plus d'épisodes